SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending significantly following its strong quarterly performance and an exceptionally optimistic outlook, primarily fueled by booming demand for its high-bandwidth memory chips in the expanding AI market. This has sparked intense community discussion about the sustained strength of the AI and semiconductor sectors, with many watching to see if Micron's results can provide a positive catalyst for the broader tech segment.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending after unveiling plans to expand into traditional U.S. stock and ETF trading, alongside new prediction markets and asset tokenization features. This strategic pivot aims to establish Coinbase as an 'everything app' platform, diversifying its offerings beyond core crypto and competing with traditional brokerages. The community is actively debating if this move solidifies its long-term potential or if it signals a retreat from its crypto-first identity, with reactions ranging from excitement over innovation to skepticism about its timing and competitive edge.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to the recent completion of its Roboteam acquisition, significantly expanding its multi-domain autonomous systems portfolio, and a new strategic partnership with German manufacturer HEIDELBERG to localize European drone production. The community is actively discussing these developments, alongside the CEO's increased stake and potential major defense contracts, fueling strong conviction for long-term growth in the rapidly expanding drone and counter-UAS market.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Processa Pharmaceuticals (PCSA) is trending following positive clinical trial data for its NGC-Cap breast cancer treatment, which reportedly enhances efficacy without increasing side effects. This news, coupled with a recent reverse stock split and a perceived small float, has sparked intense retail investor interest and speculation about a potential short squeeze, even as some community members caution against a possible pump-and-dump and future dilution risks.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore (SOC) is trending after the federal Pipeline and Hazardous Materials Safety Administration (PHMSA) confirmed its pipeline as an interstate facility, implying federal jurisdiction over California. This has ignited community discussion, with many anticipating a potential restart and a significant price movement. However, others express caution, highlighting ongoing California regulatory challenges and past liquidity concerns as potential obstacles.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively discussed ahead of an anticipated address by Donald Trump, sparking highly polarized community perspectives. While supporters hope for positive announcements and a strong economic outlook, critics view the event as a potential diversion from underlying financial performance or the upcoming release of significant legal documents. The stock's movement is notably driven by these political narratives rather than traditional business fundamentals.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending amid a sharp sector-wide pullback, fueled by recent news impacting data center financing and renewed concerns about the broader AI market. Community discussion reflects a mix of frustration over the rapid decline and conviction among long-term holders who see this as a significant buying opportunity while awaiting news on new hyperscaler client announcements.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending following an earnings beat, a significant share buyback authorization, and the anticipated departure of its CEO. Community discussion highlights the activist stake by Elliott Investment Management and widespread optimism that new leadership, combined with strong international growth, could drive a turnaround for the premium athletic apparel brand. Investors are actively debating the potential for this confluence of events to reshape LULU's trajectory.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus ($NUKK) is largely trending due to an anticipated shareholder vote concerning the full acquisition of Star 26 Capital, a company with ties to the Iron Dome defense system. The community is keenly divided, with many bullish on potential short squeezes and significant growth from expanding defense contracts, while others express caution regarding recent share issuance and the stock's volatility. This strategic move into aerospace and defense continues to generate intense discussion among investors monitoring NUKK's long-term trajectory.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin, a Solana-based token, is trending with a strong community narrative positioning it as "Bitcoin but way higher" and linking directly to the evolving cannabis culture. Discussion centers on its potential for significant upside as a meme coin, alongside aspirations for cannabis to "flip big pharma" through its medicinal and environmental benefits. Despite some skepticism, its grassroots momentum within the broader crypto and cannabis sectors continues to drive widespread conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw some unusual options trading activity on Tuesday. Investors bought 12,807 call options on the stock. This is an increase of 1,592...

<ul class="summary-bullets"><li>The FDA delayed its decision on the dry eye drug Reproxalap without raising new issues.</li><li>The FDA pushed the PDUFA deadline to March 16, 2026, after requesting a clinical study report already reviewed under an earlier filing.</li><li>Regulatory progress continued, with the FDA sharing a draft label and outlining next steps.</li></ul>Aldeyra Therapeutics shares jumped on Tuesday, heading for their best day in more than eight months, after the U.S. Food and Drug Administration (FDA) extended its review of the company’s dry eye drug without flagging any new issues.The stock rose 31% to hit $5.22 at the time of writing.<h2 class="st-heading-2">FDA Timeline</h2>Aldeyra Therapeutics said the FDA has pushed back its decision deadline on Reproxalap, the company’s dry eye drug, to March 16, 2026. The deadline, known as the Prescription Drug User Fee Act target action date, had previously been set for Dec. 16.The extension follows a Dec. 12 meeting between the FDA and the company, during which the agency requested submission of a Clinical Study Report for a dry eye disease field trial. Aldeyra said the report was submitted to the NDA on the same day and was classified by the FDA as a major amendment, triggering the three-month extension.<h2 class="st-heading-2">Scope Of The FDA Request</h2>The company said the FDA made no other requests at the December meeting and did not identify any additional issues with the NDA review. The Clinical Study Report had already been reviewed by the FDA under the drug’s Investigational New Drug file.Aldeyra also said safety data from the field trial had been submitted earlier, in August, at the FDA’s request during the NDA review process.The field trial, for which top-line results were announced in May, did not meet its primary endpoint of improving dry eye symptoms compared with a vehicle control. The company said the trial was supportive of the activity of the drug relative to the vehicle and had been discussed with the FDA before the NDA submission.<h2 class="st-heading-2">Labeling Progress&nbsp;</h2>Earlier this month, the FDA shared a draft of the proposed label for the dry eye drug with Aldeyra, and the company said it has submitted a response. According to Aldeyra, the FDA indicated that if no major deficiencies are identified during the extended review period, the agency plans to communicate proposed labeling requests and any anticipated postmarketing requirements by Feb. 16, 2026.Aldeyra said the NDA was originally submitted on June 16, and was accepted for review as a complete class 2 response in July.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Aldeyra was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:972/136;" src="https://news.stocktwits-cdn.com/aldx_ss_png_1199f19110.webp" alt="aldx ss.png" width="972" height="136"><figcaption>ALDX sentiment and message volume as of December 16| Source: Stocktwits</figcaption></figure>One bullish user expects the stock to “keep rising during the day.”<stembedurl>https://stocktwits.com/MUBSN/message/639307502</stembedurl>Another user said, “Abbvie buy this bad boy out!”<stembedurl>https://stocktwits.com/GhostLegend/message/639301686</stembedurl><a href="https://stocktwits.com/symbol/ALDX">Aldeyra’s stock</a> has risen 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.

Equity

683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX

683 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 126.9% during the second quarter, according to the company in its most recent 13F filing with...

Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC lessened its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 44.3% in the second quarter, according to the company in its most recent Form 13F...

Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX

Kennondale Capital Management LLC trimmed its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 62.5% in the second quarter, according to its most recent disclosure with the...

Savant Capital LLC Makes New $552,000 Investment in Aldeyra Therapeutics, Inc. $ALDX

Savant Capital LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at...

Aldeyra Therapeutics (NASDAQ:ALDX) Given Buy Rating at BTIG Research

BTIG Research reissued a "buy" rating and issued a $9.00 price target on shares of Aldeyra Therapeutics in a report on Monday...

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...

Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the...

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.16	--	--	N/A
Q3 '25	-$0.13	--	--	N/A
Q2 '25	-$0.19	-$0.16	14.29%	BEAT
Q1 '25	-$0.27	--	--	N/A
Q4 '24	-$0.26	--	--	N/A

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALDX News

ALDXAldeyra Therapeutics Inc